AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, FY2025
8,400
Period ended Dec 31, 2025
Change on a year earlier
+9.7%
7,656 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8,400 | +9.7% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 7,656 | +28.4% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 5,963 | +36.1% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 4,381 | +46.0% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 3,000 | +53.1% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 1,959 | +27.0% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 1,543 | +10.9% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 1,391 | +29.5% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 1,074 | +28.6% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 835 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up farxiga / forxiga (dapagliflozin) — worldwide product sales ($m)
- Farxiga / Forxiga (dapagliflozin) — Worldwide YoY actual (%)10.0% · FY2025
- Farxiga / Forxiga (dapagliflozin) — Worldwide YoY CER (%)9.0% · FY2025
- Farxiga / Forxiga (dapagliflozin) — US product sales ($M)1,730 · FY2025
- Farxiga / Forxiga (dapagliflozin) — Emerging Markets product sales ($M)3,324 · FY2025
- Farxiga / Forxiga (dapagliflozin) — Europe product sales ($M)2,941 · FY2025
- Farxiga / Forxiga (dapagliflozin) — Established RoW product sales ($M)405 · FY2025
Cite this data
StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_farxiga_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.